#ESMO26: Disappointing results with mFOLFIRINOX chemotherapy intensification in the phase III IROCAS #ClinicalTrial reinforces how much work remains to be done in high-risk, locally advanced #ColonCancer, as discussed by @JenSeligmann#InsightsbyESMO
➡️ https://t.co/XBJSlnoBDr
👏👏👏
FOxTROT 5 testing peri-op dostarlimab in MSI-H locally advanced colon cancer in older or frail patients. Thanks to our fantastic 🇬🇧 investigators.
FOxTROT 6 to follow soon….
@yorkshirecancer@adbeggs@JenSeligmann@LTHTResearch
🆕Article of the Month podcast🎧: @tompowles1 discusses the FOxTROT trial in locally advanced colon cancer with @JenSeligmann
https://t.co/lBPCs1rfXk
For the full study report see:
https://t.co/iHqyDjfwSE
Neoadjuvant IO for locally advanced MSS colon ca….
This article helps us take a further step forward by demonstrating clear efficacy and signals towards biomarkers for pt selection.
💥💥huge congrats to my team neoadjuvant dear friend and team!
We will get there in colon cancer
Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO#ESMO25. Preview: https://t.co/KR6mBytwV3 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.
@aparna1024 Ah…the FOxTROT and NICHE-2 teams are working on the staging and identification of high risk pt at baseline.
With disappointing DYNAMIC-3 results and clear disadvantage for T4 pts the need is clear!
As you say presenting option to pt key
@nicholasklemen@GIMedOnc Good points.
My views…
We’ll be trialling NOM with strict surveillance schedule akin to rectal in FOxTROT 6.
Await recurrence strategy - 50% will not be cured. Best to treat optimally in curative setting but concede risk of tox esp long term endocrinopathies
@RenoHemonc Good question. Issue is nodal staging in MSI-H pts. Trust T stage more! For me >15% relapse vs 0% with IO. I think this is meaningful & should be discussed with pts
Proud to present combined NICHE-2 & FOXTROT analysis in dMMR locally advanced CC
-Neoadjuvant IO superior to chemo
-20% relapses with chemo in "good prognosis" group; 30% if T4
-Minimal path response to chemo
- Clinical staging identified high risk group
My take homes....
Further support of neoadjuvant IO esp for high risk pts
Chemo no or limited role for dMMR early CC (?ATOMIC strategy)
Clinical staging CAN identify high risk pts
20% recurrence relevant when effective rx available!
@MyriamChalabi@CRUKresearch@oncodaily
NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬
In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable.
💊 Neoadjuvant nivolumab + ipilimumab →
• 99% pathologic response
• 67% pathologic CR
• Zero recurrences to date at 3 years
🪦 This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago.
The real question now: with Cercek’s rectal data, can we safely omit surgery next?
At minimum, this should be the new standard.
At maximum, it’s the start of a paradigm shift.
@OncoAlert@TheGutOncLab #ESMO25
Durvalumab & tremelimumab + local partial tumour ablation in pts with unresectable liver mts from mCRC: results of the EORTC-1560-GITCG ph II study (ILOC) in @ESMO_Open. No benefit with ICIs combination in this pts group with high therapeutic unmet need. https://t.co/8nGqi5U03Z
🎆 Now online - my 2 fav topics in one paper
👍FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer
👍Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected pts
❓Time to re-think targeted agents in LACC/LARC
https://t.co/wDhAkgCYw5
🤔Pani had little effect on path response
👍Prospective trial in LACC RAS/RAF-wt EREG/AREG pts planned
❓Consider in LARC
This will be my last tweet - hope to see you on Bluesky 👋
@b